Small Pharmaceuticals
Market Cap
₹5,674 ₹5,674 Cr.
P/E
19.39
PEG
1.88
PEG = P/E ÷ 5yr Forward EPS CAGR
5yr Forward EPS CAGR Thesis - Base Case

- The base case depends on a gradual Domestic Formulations recovery plus a sustained Export Formulations recovery, with both together driving most incremental revenue.- The bear case is triggered by export recovery delays concurrent with domestic run-rate weakness; the bull case requires faster export conversion and stronger domestic sales.
- Watch regulatory approvals, US supply recovery, and domestic secondary-sales disclosures as the key validation points.

Key Ratios

Market cap
Market cap
5,674 Cr
PE
PE
19.39
Prom Holding
Prom Holding
69.66 %
ROE (%)
ROE (%)
11.70
ROCE (%)
ROCE (%)
11.70
Div Yield (%)
Div Yield (%)
-
Sales
Sales
2,190 Cr
OPM (%)
OPM (%)
15.32 %
Debt to Equity
Debt to Equity
-
Institutions
Institutions
7.71 %
Individual < 2 lac
Individual < 2 lac
13.41 %
No. of Shareholders
No. of Shareholders
55,045

About

Founded in 1936, FDC Limited is a leading pharmaceutical company in India, known for specializ… Read more
Low
313
52W Range
High
528
  • FDC
  • Orchid Pharma
  • Guj. Themis Biosyn
  • TJI Pharma - Small Cap

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statement

Edit rows

Forensics

9 Yes

Positive for this company

2 Neutral

Neutral for this company

6 No

Negative for this company

0 No Data

Insufficient data to analyse

Market Share

0.15 %
(as of Jul 22)
Anti - Diabetes - Market Share
2.78 %
(as of Jul 22)
Anti-Infectives - Market Share
0.03 %
(as of Feb 21)
Anti-Malarial - Market Share
0.75 %
(as of Nov 21)
Blood Related - Market Share
0.29 %
(as of Jul 22)
Cardiovascular - Market Share
0.54 %
(as of Nov 21)
Dermatology - Market Share

Revenue mix

Product Wise Break-Up

Therapeutic Area Wise Break-Up - Domestic

Location Wise Break-Up - Formulation

Location Wise Break-Up - Bulk Drugs

Location Wise Break-Up

Operational Metrics

    Select a Metric
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Brands

    Electral

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    Suppliers

    • Sayaji Industries Ltd.

    FAQs on FDC Ltd. Business

    FDC Limited is a renowned pharmaceutical company in India, established in 1936. It focuses on producing top-notch products such as Oral Rehydration Salts (ORS) and prescription formulations with internationally accredited manufacturing units.

    FDC major competitors are Orchid Pharma, Guj. Themis Biosyn, Bliss GVS Pharma, Gufic Biosciences, Novartis India, Sanofi India, Unichem Laboratories.
    Market Cap of FDC is ₹5,674 Crs.
    While the median market cap of its peers are ₹5,569 Crs.

    FDC seems to be less financially stable compared to its competitors.
    Altman Z score of FDC is 10.27 and is ranked 5 out of its 8 competitors.

    Company Filing

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material